15-hydroxy Prostaglandin Dehydrogenase D50H variant (human, recombinant)

15-hydroxy Prostaglandin dehydrogenase (PGDH) is an enzyme of the short-chain alcohol dehydrogenase family that catalyzes the oxidation of prostaglandins to 15-keto metabolites with reduced biological activity. It uses NAD+ as a cofactor and, in addition to PGs, also converts various hydroxy fatty acids, such as HETEs, resolvins, and lipoxins, to less active keto metabolites. 15-PGDH acts as a tumor suppressor, and restoring HPGD, the gene encoding 15-PGDH, expression in human colon cancer cells in vitro reduces subsequent tumor formation in mouse xenograft models. Knockout of Hpgd or inhibition of 15-PGDH in mice increases hepatic tissue regeneration and induces resistance to ulcerative colitis. Inhibition of 15-PGDH also increases mitochondrial function and autophagic flux in muscle tissue, as well as increases muscle mass and strength in aged mice. Cayman's 15-PGDH D50H variant (human, recombinant) protein contains an aspartate-to-histidine substitution at position 50 (D50H) and can be used for enzyme assay and Western blot (WB) applications.Synonyms: NAD+-dependent 15-hydroxy Prostaglandin Dehydrogenase, Prostaglandin Dehydrogenase 1, Short-chain Dehydrogenase/Reductase Family 36C Member 1. Purity: >90% estimated by SDS-PAGE. Source: Active recombinant human C-terminal His-tagged 15-PGDH expressed in E. coli. Amino Acids: 3-256. MW: 29.9 kDa. Formulation: (Request formulation change), 50 mM potassium phosphate, pH 7.6, with 150 mM sodium chloride, 1 mM EDTA, 0.1 mM DTT, and 5% glycerol. UniProt Accession #: P15428.